BioCentury
ARTICLE | Clinical News

MitoQ: Phase II data

April 28, 2008 7:00 AM UTC

In a double-blind, New Zealand Phase II trial in 30 HCV patients, MitoQ met the primary endpoint of significantly reduced ALT levels vs. placebo. Compared with placebo, patients receiving 40 or 80 mg/...